Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.

GUD Insider Trading (Knight Therapeutics)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$1,095,637.90
Insider Selling (Last 12 Months): C$0.00

Knight Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Knight Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Knight Therapeutics Share Price & Price History

Current Price: C$5.31
Price Change: Price Increase of +0.1 (1.92%)
As of 05/20/2022 01:00 AM ET

This chart shows the closing price history over time for GUD up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.

Knight Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/18/2022Long Zone Holdings Inc. InsiderBuy20,000C$5.17C$103,400.0021,705,933
5/18/2022Samira SakhiaDirectorBuy19,305C$5.18C$99,999.90136,734
4/13/2022Janice Jean MurrayDirectorBuy1,900C$5.30C$10,070.006,115
12/23/2021Jonathan Ross GoodmanDirectorBuy3,600C$5.24C$18,864.00765,059
12/13/2021Samira SakhiaDirectorBuy15,800C$5.20C$82,160.0083,786
12/3/2021Jonathan Ross GoodmanDirectorBuy19,200C$5.21C$100,032.00
11/22/2021Jonathan Ross GoodmanDirectorBuy800C$5.23C$4,184.00672,984
11/22/2021Long Zone Holdings Inc. InsiderBuy18,000C$5.29C$95,220.0021,685,133
11/19/2021Robert Nathaniel LandeDirectorBuy15,000C$5.39C$80,850.00260,614
11/19/2021Robert Nathaniel LandeDirectorBuy15,000C$5.39C$80,850.00260,614
11/15/2021Jonathan Ross GoodmanDirectorBuy18,000C$5.25C$94,500.00654,184
9/20/2021Arvind UtchanahSenior OfficerBuy600C$5.20C$3,120.009,913
8/23/2021Jonathan Ross GoodmanDirectorBuy4,300C$5.36C$23,048.00631,788
8/18/2021Jonathan Ross GoodmanDirectorBuy18,000C$5.39C$97,020.00609,488
7/14/2021Jonathan Ross GoodmanDirectorBuy18,000C$5.30C$95,400.00591,488
7/2/2021Jonathan Ross GoodmanDirectorBuy18,000C$5.24C$94,320.00555,488
5/25/2021Jonathan Ross GoodmanDirectorBuy2,400C$5.25C$12,600.00502,361
1/13/2021Robert Nathaniel LandeDirectorBuy17,000C$5.27C$89,590.0072,714
1/6/2021Long Zone Holdings Inc. InsiderBuy200C$5.29C$1,058.0021,656,133
9/15/2020Robert Nathaniel LandeDirectorBuy414C$6.04C$2,500.5646,128
7/11/2019Robert Nathaniel LandeDirectorBuy20,000C$7.52C$150,300.0045,392
6/21/2019Long Zone Holdings Inc. InsiderBuy12,000C$7.59C$91,080.0021,633,433
See Full Table
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.

SEC Filings (Institutional Ownership Changes) for Knight Therapeutics (TSE:GUD)

Knight Therapeutics logo
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.
Read More on Knight Therapeutics

Today's Range

Now: C$5.31
Low: C$5.22
High: C$5.38

50 Day Range

MA: C$5.34
Low: C$5.18
High: C$5.65

52 Week Range

Now: C$5.31
Low: C$5.01
High: C$5.74

Volume

119,043 shs

Average Volume

231,313 shs

Market Capitalization

C$612.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Knight Therapeutics?

Knight Therapeutics' top insider shareholders include:
  1. Long Zone Holdings Inc (Insider)
  2. Jonathan Ross Goodman (Director)
  3. Robert Nathaniel Lande (Director)
  4. Samira Sakhia (Director)
  5. Arvind Utchanah (Senior Officer)
  6. Janice Jean Murray (Director)
Learn More about top insider investors at Knight Therapeutics.
How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.